Subscribe To
CCCC / C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
CCCC News
By Zacks Investment Research
May 4, 2023
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares t more_horizontal
By Zacks Investment Research
February 23, 2023
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the more_horizontal
By Benzinga
April 8, 2022
Why C4 Therapeutics Stock Is Plunging Today
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongo more_horizontal
By Benzinga
April 8, 2022
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgk more_horizontal